树突状细胞抗肿瘤免疫的研究进展  

Research advance in dendritic cells anti-tumor immunity

作　　者：罗善超[1] 刘剑勇[1] 

机构地区：[1]广西医科大学研究生学院2004级,广西南宁530021

出　　处：《世界肿瘤杂志》2006年第2期128-131,共4页Tumour Journal of the World

基　　金：广西科学研究与技术开发计划项目（桂科攻0143052）

摘　　要：树突状细胞（dendritic cell，DC）是功能最强的抗原呈递细胞（antigen presenting cell，APC）。DC均来源于体内多能造血干细胞，主要分为髓系DC与淋巴系DC；按发育程度分为不成熟DC和成熟DC；按诱导免疫反应分为DC1和DC2两个亚群。DC前体细胞由骨髓进入外周血，再分布到全身各组织。DC可通过摄取、加工和提呈抗原，在其表面表达大量的MHC-肽复合物，上调共刺激分子及向外周淋巴组织迁移等作用，激活T细胞和诱导机体产生特异性免疫反应。目前，无论在动物模型和人体实验都可以用多种不同的前体细胞沿不同的分化途径在体外诱导扩增DC。以DC为基础的肿瘤疫苗已被广泛研究并应用于临床。Dendritic cells （DC） are the most potent antigenpresenting cells （APCs）. DC all derives trommultipotent hemopoietic stem cell in vivo, mainly including myeloid and lymphoid system DC; immature and mature DC according to DC maturation status; DC1 and DC2 subgroup according to the ability to inducing immunereaction. DC precursor goes into peripheral blood from marrow, then redistributes into quaque tissue all over the body. DC can stimulate T cell and induce specific immunity by capturing, handling and presenting antigen, releasing abundant MHC class/peptide complexes on its surface, uptaking costimulatory molecules, migrating into peripheral lymphoid tissue, and so on. At present, there are many kinds of ways to induce DC precursor into DC in animal model and human experiment in vitro. Tumor vaccine basis on DC have been generally studied and also applied to clinical application.

关 键 词：树突状细胞 癌症疫苗 肿瘤免疫 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]